# A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

> **NCT05186506** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 152 (estimated)

## Conditions studied

- ALK Fusion Protein Expression
- Adjuvant Therapy
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ensatinib
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT05186506
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2025-12-15
- **Final completion:** 2028-12-20
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186506, "A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05186506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*